Tirzepatide
Tirzepatide works by stimulating both GLP-1 and GIP receptors, resulting in combined benefits for controlling appetite, boosting insulin secretion, and regulating metabolism. This dual action promotes insulin release in response to blood glucose levels, while also lowering glucagon output and delaying stomach emptying.
Also known as: Mounjaro, Zepbound, LY3298176
A next-generation incretin therapy that acts as a dual agonist of the GIP and GLP-1 receptors. In direct comparative studies, it has demonstrated greater weight loss efficacy than semaglutide.
•Status: Approved by the FDA. Evidence level: Confirmed by FDA approval.
•Standard dosage: 5–15 mg once weekly (following dose escalation). Administered via weekly subcutaneous injection.
•Investigated for use in: Weight management, type 2 diabetes treatment, and overall metabolic health improvement.
Reviews
There are no reviews yet.